Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP)

Peptides

Volumn 19, Issue 9, 1998, Pages 1511-1517

  Haidan, A ^a,d   Hilbers, U ^a   Bornstein, S R ^a,b   Ehrhart Bornstein, M ^a,c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

NCI H295; Steroidogenesis; VIP; VIP receptors

Indexed keywords

ALDOSTERONE; HYDROCORTISONE; PRASTERONE; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ADRENAL CORTEX CARCINOMA; ALDOSTERONE RELEASE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HORMONE ACTION; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROIDOGENESIS;

ADRENAL CORTEX; ADRENAL CORTEX HORMONES; ADRENAL CORTEX NEOPLASMS; ALDOSTERONE; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROCORTISONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032444027     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(98)00115-6     Document Type: Article

References (39)

1. Andersson, M.; Sillard, R.; Rokaeus, A. Demonstration of [125I]VIP binding sites and effects of VIP on cAMP-formation in rat insulinoma (RINm5F and RIN14B) cells. Regul. Pept. 40:41-49; 1992.
2. Bernet, F.; Bernard, J.; Laborie, C.; Montel, V.; Maubert, E.; Dupouy, J. P. Neuropeptide Y (NPY)- and vasoactive intestinal peptide (VIP)- induced aldosterone secretion by rat capsule/glomerular zone could be mediated by catecholamines via beta 1 adrenergic receptors. Neurosci. Lett. 166:109-112; 1994.
3. Bird, I. M.; Hanley, N. A.; Word, R. A.; Mathis, J. M.; McCarthy, J. L.; Mason, J. I.; Rainey, W. E. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology. 133:1555-1561; 1993.
4. 1-R mRNA levels in human adrenocortical cells. Endocr. Res. 21:169-182; 1995.
5. Bodart, V.; Babinski, K.; Ong, H.; De Lean, A. Comparative effect of pituitary adenylate cyclase-activating polypeptide on aldosterone secretion in normal bovine and human tumorous cells. Endocrinology. 138:566-573; 1997.
6. Bornstein, S. R.; Gonzalez-Hernandez, J. A.; Ehrhart-Bornstein, M.; Adler, G.; Scherbaum, W. A. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the cellular basis for important intraadrenal interactions. J. Clin. Endocrinol. Metab. 78:225-232; 1994.
7. Bornstein, S. R.; Haidan, A.; Ehrhart-Bornstein, M. Cellular communication in the neuro-adrenocortical axis: role of vasoactive intestinal polypeptide (VIP). Endocr. Res. 22:819-829; 1996.
8. Ehrhart-Bornstein, M.; Bornstein, S. R.; Scherbaum, W. A.; Pfeiffer, E. F.; Holst, J. J. Role of vasoactive intestinal peptide in a neuroendocrine regulation of the adrenal cortex. Neuroendocrinology. 54:623-628; 1991.
9. Ehrhart-Bornstein, M.; Hilbers, U. Neuroendocrine properties of adrenocortical cells. Horm. Metab. Res. 30:436-439; 1998.
10. Ehrhart-Bornstein, M.; Hinson, J. P.; Bornstein, S. R.; Scherbaum, W. A.; Vinson, G. P. Intra-adrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr. Rev. 19:101-143; 1998.
11. Gamet, L.; Murat, J. C.; Remaury, A.; Remesy, C.; Valet, P.; Paris, H.; Denis-Pouxviel, C. Vasoactive intestinal peptide and forskolin regulate proliferation of the HT29 human colon adenocarcinoma cell line. J. Cell. Physiol. 150:501-509; 1992.
12. Gazdar, A. F.; Oie, H. K.; Shackleton, C. H.; Chen, T. R.; Triche, T. J.; Myers, C. E.; Chrousos, G. P.; Brennan, M. F.; Stein, C. A.; La Rocca, R. V. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50:5488-5496; 1990.
13. Glasow, A.; Breidert, M.; Haidan, A.; Anderegg, U.; Kelly, P. A.; Bornstein, S. R. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J. Clin. Endocrinol. Metab. 81:3103-3111; 1996.
14. Haidan, A.; Bornstein, S. R.; Glasow, A.; Uhlmann, K.; Lübke, C.; Ehrhart-Bornstein, M. Basal steroidogenic activity of adrenocortical cells is increased 10-fold by coculture with chromaffin cells. Endocrinology. 139:772-780; 1998.
15. Heym, C.; Colombo-Benckmann, M.; Mayer, B. Immunohistochemical demonstration of the synthesis enzyme for nitric oxide and of comediaters in neurons and chromaffin cells of the human adrenal medulla. Anat. Anz. 176:11-16; 1994.
16. Hinson, J. P.; Kapas, S.; Orford, C. D.; Vinson, G. P. Vasoactive intestinal peptide stimulation of aldosterone secretion by the rat adrenal cortex may be mediated by the local release of catecholamines. J. Endocrinol. 133:253-258; 1992.
17. Jiang, S.; Kopras, E.; McMichael, M.; Bell, R. H.; Ulrich, C. D. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res. 57:1475-1480; 1997.
18. Lacroix, A.; Bolté, E.; Tremblay, J.; Dupré, J.; Poitras, P.; Fournier, H.; Garon, J.; Garrel, D.; Bayard, F.; Taillefer, R. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's syndrome. N. Engl. J. Med. 327:974-980; 1992.
19. 1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome and orthostatic hypotension. J. Clin. Endocrinol. Metab. 8:2414-2422; 1997.
20. Latronico, A. C.; Chrousos, G. P. Extensive personal experience: adrenocortical tumors. J. Clin. Endocrinol. Metab. 82: 1317-1324; 1997.
21. Lilling, G.; Wollman, Y.; Goldstein, M. N.; Rubinraut, S.; Fridkin, M.; Brenneman, D. E.; Gozes, I. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J. Mol. Neurosci. 5:231-239; 1994.
22. Maruno, K.; Said, S. I. Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody. Life Sci. 52:PL267-71; 1993.
23. Moody, T. W.; Zia, F.; Draoui, M.; Brenneman, D. E.; Fridkin, M.; Davidson, A.; Gozes, I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. USA. 90:4345-4349; 1993.
24. Mountjoy, K. G.; Bird, I. M.; Rainey, W. E.; Cone, R. D. ACTH induces up-regulation of ACTH receptor mRNA in mouse and human adrenocortical cell lines. Mol. Cell. Endocrinol. 99:R17-R20; 1994.
25. Perraudin, V.; Delarue, C.; De Keyzer, Y.; Bertagna, X.; Kuhn, J.-M.; Contesse, V.; Clauser, E.; Vaudry, H. Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 80:2661-2667; 1995.
26. Rainey, W. E.; Bird, I. M.; Mason, J. I. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Mol. Cell. Endocrinol. 100:45-50; 1994.
27. 19 Steroids. J. Clin. Endocrinol. Metab. 77:731-737; 1993.
28. Reincke, M.; Mora, P.; Beuschlein, F.; Arlt, W.; Chrousos, G. P.; Allolio, B. Deletion of adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 82:3054-3058; 1997.
29. Reubi, J. C. The role of peptides and their receptors as tumor markers. Endocrinol. Metab. Clin. North Am. 22:917-939; 1993.
30. Reubi, J. C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J. Nucl. Med. 36:1846-1853; 1995.
31. Reznik, Y.; Allali-Zerah, V.; Chayvialle, J. A.; Leroyer, R.; Leymarie, P.; Travert, G.; Lebrethon, M. C.; Budi, I.; Balliere, A. M.; Mahoudeau, J. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N. Engl. J. Med. 327:981-986; 1992.
32. Rosselin, G.; Maletti, M.; Besson, J.; Rostene, W. A new neuroregulator: the vasoactive intestinal peptide or VIP. Mol. Cell. Endocrinol. 27:243-262; 1982.
33. Said, S. I. Vasoactive intestinal polypeptide (VIP): Current status. Peptides. 5:143-150; 1984.
34. Svoboda, M.; Tastenoy, M.; Rampelbergh, J. V.; Goossens, J.-F.; De Neef, P.; Waelbroeck, M.; Robberecht, P. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205:1617-1624; 1994.
35. Virgolini, I.; Kurtaran, A.; Raderer, M.; Leimer, M.; Angelberger, P.; Havlik, E.; Li, S.; Scheithauer, W.; Niederle, B.; Valent, P.; Eichler, H.-G. Vasoactive intestinal peptide receptor scintigraphy. J. Nucl. Med. 36:1732-1739; 1995.
36. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Banyai, S.; Yang, Q.; Li, S.; Banyai, M.; Pidlich, J.; Niederle, B.; Scheithauer, W.; Valent, P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331:1116-1121; 1994.
37. Virgolini, I.; Yang, Q.; Li, S.; Angelberger, P.; Neuhold, N.; Niederle, B.; Scheithauer, W.; Valent, P. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 54: 690-700; 1994.
38. Willenberg, H. S.; Stratakis, C. A.; Marx, C.; Ehrhart-Bornstein, M.; Chrousos, G. P.; Bornstein, S. R. Aberrant interleukin-1 (IL-1) receptors in cortisol-secreting adrenal adenoma causing Cushing's syndrome. N. Engl. J. Med. 339:27-31; 1998.
39. Zia, H.; Hida, T.; Jakowlew, S.; Birrer, M.; Gozes, Y.; Reubi, J. C.; Fridkin, M.; Gozes, I.; Moody, T. W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56: 3486-3489; 1996.